Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT06502366

PHASE3

A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

Sponsor: AstraZeneca

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the PD equivalence of the approved asthma combination therapy, BDA, delivered using the proposed replacement propellant HFO compared with BDA delivered using the currently approved propellant HFA in participants with asthma.

Official title: A Randomized, Placebo-controlled, Double-blind, Multicenter, 12-Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared With BDA Delivered by MDI HFA in Participants With Asthma

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

422

Start Date

2024-07-22

Completion Date

2026-03-03

Last Updated

2026-02-13

Healthy Volunteers

Conditions

Asthma

Interventions

DRUG

BDA MDI HFO 160/180 μg

Budesonide/albuterol pressurized inhalation suspension, HFO

DRUG

BDA MDI HFA 160/180 μg

Budesonide/albuterol pressurized inhalation suspension, HFA

DRUG

Placebo MDI HFA

Placebo pressurized inhalation suspension, HFA

Inclusion Criteria: * Participant must be ≥ 18 years of age at the time of signing the ICF. * Participants who have physician diagnosed asthma as defined by GINA for at least 12 months prior to Visit 1. * Eligible participants are on either a) no daily inhaled maintenance therapy or b) daily inhaled maintenance therapy with low-dose ICS or low-dose ICS-LABA. Participants who are on low-dose ICS maintenance therapy are required to be stable on therapy for a minimum of 3 months prior to Visit 1; participants using low-dose ICSLABA maintenance regimens are required to be stable on therapy for a minimum of 6 months prior to Visit 1. * Participants with a pre-bronchodilator FEV1 of ≥ 60% and \< 90% predicted normal at Visit 1 or Visit 1a. * Participants with a pre-dose FEV1 of ≥ 60% and \< 90% predicted normal at Visit 2 that is within ± 20% of their Visit 1 pre-bronchodilator FEV1. * Participants who demonstrate bronchodilator responsiveness defined as a \> 12% and \> 200 mL increase in FEV1 relative to baseline following administration of study provided SABA at Visit 1 or Visit 1a. * Participants able to demonstrate acceptable spirometry performance as defined by the acceptability and repeatability criteria in the ATS/ERS Standardization of Spirometry 2019 update * Participants who are willing and, in the opinion of the investigator, able to adjust current asthma therapy, as required by the protocol. * Participants with a body mass index \< 40 kg/m2. * Females must not be of childbearing potential or, if of childbearing potential, using a form of birth control Exclusion Criteria: * Confirmed or suspected diagnosis of COPD or clinically significant non-asthma airway/lung disease. * Systemic corticosteroid use (eg, prednisone for 3 or more days or a single depo-injectable dose of corticosteroids) for any respiratory, immune, or allergy-attributed disease within 6 months prior to Visit 1. * An upper respiratory infection requiring antibiotic treatment that is not resolved within 7 days prior to Visit 1. * A lower respiratory infection in the 4 weeks prior to Visit 1. * Life-threatening asthma defined as any history of significant asthma episode(s) requiring admission to an intensive care unit, positive pressure ventilation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s) within 5 years of Visit 1. * Hospitalization due to asthma within 12 months or systemic corticosteroid usage (eg, prednisone for 3 or more days or a single depo-injectable dose of corticosteroids) for asthma within 6 months prior to Visit 1. * A severe asthma exacerbation during the run-in period * An ePRO device alert during the run-in period with investigator-confirmed worsening asthma symptoms * Historical or current evidence of a clinically significant disease including, but not limited to: cardiovascular (eg, congestive heart failure, known aortic aneurysm, clinically significant cardiac arrhythmia, coronary heart disease), hepatic, renal, hematological, neuropsychological, endocrine (eg, uncontrolled diabetes mellitus, uncontrolled thyroid disorder, Addison's disease, Cushing's syndrome), or gastrointestinal (eg, poorly controlled peptic ulcer, gastroesophageal reflux disease) disorders. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the participant at risk through study participation or that could affect the efficacy or safety analyses if the disease/condition exacerbated during the study. * Unresectable cancer that has not been in complete remission for at least 5 years prior to Visit 1 * Hospitalization for psychiatric disorder or attempted suicide within 1 year of Visit 1. * Known history of drug or alcohol abuse within 12 months of Visit 1 or known abuse at any time during the study.

Locations (128)

Research Site

Mobile, Alabama, United States

Research Site

Sheffield, Alabama, United States

Research Site

Phoenix, Arizona, United States

Research Site

Little Rock, Arkansas, United States

Research Site

Encinitas, California, United States

Research Site

Fullerton, California, United States

Research Site

Gardena, California, United States

Research Site

Huntington Beach, California, United States

Research Site

La Mesa, California, United States

Research Site

Los Angeles, California, United States

Research Site

Los Angeles, California, United States

Research Site

Sacramento, California, United States

Research Site

San Bernardino, California, United States

Research Site

San Diego, California, United States

Research Site

San Jose, California, United States

Research Site

Santa Ana, California, United States

Research Site

Stockton, California, United States

Research Site

Westminster, California, United States

Research Site

Englewood, Colorado, United States

Research Site

Wheat Ridge, Colorado, United States

Research Site

Washington D.C., District of Columbia, United States

Research Site

Boynton Beach, Florida, United States

Research Site

Miami, Florida, United States

Research Site

Tallahassee, Florida, United States

Research Site

Tampa, Florida, United States

Research Site

Atlanta, Georgia, United States

Research Site

Rincon, Georgia, United States

Research Site

Savannah, Georgia, United States

Research Site

Meridian, Idaho, United States

Research Site

River Forest, Illinois, United States

Research Site

Evansville, Indiana, United States

Research Site

Valparaiso, Indiana, United States

Research Site

Sioux City, Iowa, United States

Research Site

Louisville, Kentucky, United States

Research Site

Lafayette, Louisiana, United States

Research Site

New Orleans, Louisiana, United States

Research Site

White Marsh, Maryland, United States

Research Site

Flint, Michigan, United States

Research Site

Columbia, Missouri, United States

Research Site

St Louis, Missouri, United States

Research Site

Omaha, Nebraska, United States

Research Site

Monticello, New York, United States

Research Site

New York, New York, United States

Research Site

Watertown, New York, United States

Research Site

Charlotte, North Carolina, United States

Research Site

Raleigh, North Carolina, United States

Research Site

Cincinnati, Ohio, United States

Research Site

Oklahoma City, Oklahoma, United States

Research Site

Tulsa, Oklahoma, United States

Research Site

Medford, Oregon, United States

Research Site

Portland, Oregon, United States

Research Site

Pottstown, Pennsylvania, United States

Research Site

Scottdale, Pennsylvania, United States

Research Site

Greenville, South Carolina, United States

Research Site

North Charleston, South Carolina, United States

Research Site

Boerne, Texas, United States

Research Site

Dallas, Texas, United States

Research Site

DeSoto, Texas, United States

Research Site

El Paso, Texas, United States

Research Site

Kingwood, Texas, United States

Research Site

McKinney, Texas, United States

Research Site

Pearland, Texas, United States

Research Site

San Antonio, Texas, United States

Research Site

Victoria, Texas, United States

Research Site

West Jordan, Utah, United States

Research Site

Burke, Virginia, United States

Research Site

Portsmouth, Virginia, United States

Research Site

Spokane, Washington, United States

Research Site

Morgantown, West Virginia, United States

Research Site

Milwaukee, Wisconsin, United States

Research Site

Baotou, China

Research Site

Changsha, China

Research Site

Chengdu, China

Research Site

Chizhou, China

Research Site

Chongqing, China

Research Site

Guangzhou, China

Research Site

Guangzhou, China

Research Site

Haikou, China

Research Site

Hangzhou, China

Research Site

Hefei, China

Research Site

Hohhot, China

Research Site

Huizhou, China

Research Site

Jinan, China

Research Site

Jinhua, China

Research Site

Lanzhou, China

Research Site

Linhai, China

Research Site

Nanchang, China

Research Site

Pingxiang, China

Research Site

Qingdao, China

Research Site

Shanghai, China

Research Site

Shanghai, China

Research Site

Shanghai, China

Research Site

Shenyang, China

Research Site

Shenzhen, China

Research Site

Shijiazhuang, China

Research Site

Taiyuan, China

Research Site

Taiyuan, China

Research Site

Wenzhou, China

Research Site

Wuhan, China

Research Site

Xuzhou, China

Research Site

Xuzhou, China

Research Site

Yangzhou, China

Research Site

Yinchuan, China

Research Site

Zhengzhou, China

Research Site

Zhuji, China

Research Site

Cheras, Malaysia

Research Site

Petaling Jaya, Malaysia

Research Site

Chihuahua City, Mexico

Research Site

Cuernavaca, Mexico

Research Site

Culiacán, Mexico

Research Site

Durango, Mexico

Research Site

Guadalajara, Mexico

Research Site

Guadalajara, Mexico

Research Site

Mazatlán, Mexico

Research Site

Monterrey, Mexico

Research Site

Monterrey, Mexico

Research Site

San Juan del Río, Mexico

Research Site

Tijuana, Mexico

Research Site

Veracruz, Mexico

Research Site

Zapopan, Mexico

Research Site

Bangkoknoi, Thailand

Research Site

Khon Kaen, Thailand

Research Site

Mueang, Thailand

Research Site

Ratchathewi, Thailand

Research Site

Can Tho, Vietnam

Research Site

Haiphong, Vietnam

Research Site

Hanoi, Vietnam

Research Site

Ho Chi Minh City, Vietnam

Clinical Research Directory

A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (128)